Printer Friendly

Halozyme announces CRADA with VRC for use of ENHANZE technology.

Halozyme Therapeutics announced a Cooperative Research and Development Agreement, or CRADA, with the National Institute of Allergy and Infectious Diseases' Vaccine Research Center, or VRC, part of the National Institutes of Health, enabling the VRC's use of Halozyme's ENHANZE drug delivery technology to develop subcutaneous formulations of broadly neutralizing antibodies, or bnAbs, against HIV for HIV treatment. The two bnAbs selected for the CRADA are VRC07-523LS and N6LS. The VRC will engage in early phase studies in healthy adults investigating the safety, tolerability, dose, and pharmacokinetics of formulating these bnAbs with ENHANZE(R) for the purpose of optimizing subcutaneous administration of these antibodies.

COPYRIGHT 2019 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Jun 25, 2019
Previous Article:Oil Action: WTI crude.
Next Article:Bombardier to sell Canadair regional jet program to MHI for $550M.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters